BioMarin Pharmaceutical (BMRN) Earnings Date & Reports

Key Takeaways

• BioMarin Pharmaceutical is scheduled to report third quarter 2026 results after the market close on Monday, November 2, 2026, with a conference call at 4:30 p.m. ET.
• Analysts expect non-GAAP earnings per share (EPS) of roughly $1.35 and total revenues of about $1.02 billion to $1.03 billion, which would mark a year-over-year revenue increase of more than 30%.
• The quarter is the first to include a full three months of contribution from the recently acquired Amicus products, GALAFOLD and POMBILITI + OPFOLDA.
• Management guided third quarter revenue slightly above the second quarter's $989.7 million and non-GAAP EPS slightly above the $1.20 reported in the prior period.
• Investors are closely watching VOXZOGO's competitive position following the U.S. launch of a rival therapy, with about 90% of U.S. patients remaining on treatment through the end of July.
• A roughly $283 million research and development (R&D) charge tied to the Alesta acquisition is expected to weigh on third quarter GAAP results, making the non-GAAP comparison especially important.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore Tickeron's dedicated pages for additional insights.
• Explore Trending AI Robots to see AI-powered trading strategies that scan for market opportunities in real time.

Earnings Context and Why It Matters

BioMarin Pharmaceutical's third quarter report is a pivotal checkpoint for investors. The company closed its $4.8 billion acquisition of Amicus Therapeutics earlier in 2026, adding GALAFOLD for Fabry disease and POMBILITI + OPFOLDA for Pompe disease to a portfolio anchored by the blockbuster growth-hormone therapy VOXZOGO. This will be the first full quarter capturing those new products, offering a clearer read on the deal's revenue and synergy potential. At the same time, VOXZOGO faces its first meaningful competitive challenge in the United States. With management having raised full-year revenue and EPS guidance after a strong second quarter, the upcoming report will test whether that momentum is durable.

Earnings Expectations

Consensus estimates point to non-GAAP diluted EPS of approximately $1.35 for the third quarter of 2026, alongside total revenues of roughly $1.02 billion to $1.03 billion. That revenue figure implies growth of about 30% or more from the year-ago period. The spread across sources reflects differing treatment of one-time items, including a disclosed $283 million R&D charge related to the Alesta acquisition, which affects GAAP (generally accepted accounting principles) results but is excluded from non-GAAP figures.

On guidance, management indicated third quarter revenue should be slightly higher than the second quarter's $989.7 million, driven by a full quarter of Amicus contributions and continued patient growth, with non-GAAP EPS expected slightly above the prior quarter's $1.20. The company's full-year 2026 outlook calls for total revenues of $3.875 billion to $3.925 billion and non-GAAP diluted EPS of $4.90 to $5.10.

Historically, BioMarin has beaten EPS estimates in a majority of recent quarters, including a 25% surprise last quarter, when it posted $1.20 against a $0.95 consensus. However, the stock has drifted lower since that August report, making this quarter's print and any guidance update a key sentiment test.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like BioMarin or broader rare-disease and biotech themes, the tool offers a structured way to identify candidates that match specific criteria.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautiously optimistic but mixed. BioMarin carries a consensus "Moderate Buy" rating with an average analyst price target well above its recent trading range, and several firms have issued upgrades or raised targets in recent weeks. At the same time, the stock has underperformed since its last earnings release, reflecting investor uncertainty around VOXZOGO competition and the integration of the Amicus business. Key risk factors include the pace of patient switching to a competing achondroplasia therapy, the near-term earnings dilution and interest expense tied to acquisition debt, and the size of one-time charges in the quarter.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should watch several items that will shape the narrative for the rest of 2026 and into 2027.

First is the VOXZOGO franchise. The company raised its full-year VOXZOGO revenue guidance to between $1.00 billion and $1.05 billion, positioning it to become BioMarin's first billion-dollar product. With roughly 90% of U.S. patients retained on therapy despite a new competitor, the key question is whether switching stabilizes or accelerates.

Second is the Amicus integration. Management has outlined roughly $220 million in annual cost synergies by 2028 and expects the deal to be modestly dilutive in 2026 before turning accretive in 2027. Commentary on synergy timing and growth for GALAFOLD and POMBILITI + OPFOLDA will be closely scrutinized.

Third, investors should monitor the regulatory and legal calendar, including a patent case before the International Trade Commission (ITC) related to VOXZOGO, where a final decision is expected near year-end. Pipeline progress, such as the supplemental New Drug Application (sNDA) filed for VOXZOGO in hypochondroplasia, also remains a potential catalyst. As always, quarterly order-timing effects across BioMarin's enzyme therapy portfolio can create volatility in individual product revenues.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations